David Polsky

9.8k total citations · 1 hit paper
124 papers, 6.8k citations indexed

About

David Polsky is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, David Polsky has authored 124 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 66 papers in Molecular Biology and 30 papers in Cancer Research. Recurrent topics in David Polsky's work include Cutaneous Melanoma Detection and Management (69 papers), Melanoma and MAPK Pathways (34 papers) and Cancer Genomics and Diagnostics (28 papers). David Polsky is often cited by papers focused on Cutaneous Melanoma Detection and Management (69 papers), Melanoma and MAPK Pathways (34 papers) and Cancer Genomics and Diagnostics (28 papers). David Polsky collaborates with scholars based in United States, Australia and Switzerland. David Polsky's co-authors include Iman Osman, Alan N. Houghton, Carlos Cordon‐Cardo, Alfred W. Kopf, Anna C. Pavlick, Richard L. Shapiro, Russell S. Berman, Steven Q. Wang, Ashfaq A. Marghoob and Klaus J. Busam and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

David Polsky

119 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

2001 769 citations Marı́a S. Soengas, Paola Capodieci et al. Nature profile →

Peers

Countries citing papers authored by David Polsky

Since Specialization

Citations

This map shows the geographic impact of David Polsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Polsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Polsky more than expected).

Fields of papers citing papers by David Polsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Polsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Polsky. The network helps show where David Polsky may publish in the future.

Co-authorship network of co-authors of David Polsky

This figure shows the co-authorship network connecting the top 25 collaborators of David Polsky. A scholar is included among the top collaborators of David Polsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Polsky. David Polsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Navigating Melanoma In Situ in the Age of Overdiagnosis 2025 ·JAMA Dermatology ·(unknown), (unknown), Jennifer Stein, David Polsky	0
2	Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238. 2023 ·Journal of Clinical Oncology ·(unknown), Jennifer Wiggins, (unknown), (unknown), Hao Tang, (unknown), (unknown), Keyur Desai, Sonia Dolfi, Daniel J. Tenney, Paolo A. Ascierto, James Larkin, Michele Del Vecchio, Jeffrey S. Weber, David Polsky	3
3	Cutaneous melanoma incidence—Evidence of a flattening curve 2023 ·Journal of the American Academy of Dermatology ·Juliana Berk-Krauss, Medha Sharma, David Polsky, Alan C. Geller	1
4	Cell-Free DNA in Dermatology Research 2022 ·Journal of Investigative Dermatology ·Jennifer Wiggins, (unknown), David Polsky	5
5	Late-Stage Melanoma in New York State: Associations with Socioeconomic Factors and Healthcare Access at the County Level 2021 ·Journal of Investigative Dermatology ·(unknown), Yongzhao Shao, Alan C. Geller, David Polsky	11
6	Skin Lesion Segmentation and Classification with Deep Learning System. 2019 ·arXiv (Cornell University) ·(unknown), Anna Choromanska, Jennifer Stein, David Polsky, Russell S. Berman	10
7	<em>MC1R</em> variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project 2018 ·Cancer Management and Research ·Elena Tagliabue, Sara Gandini, Rino Bellocco, Patrick Maisonneuve, Julia Newton‐Bishop, David Polsky, DeAnn Lazovich, Peter A. Kanetsky, Paola Ghiorzo, Nelleke A. Gruis, Maria Teresa Landi, Chiara Menin, Maria Concetta Fargnoli, José C. García‐Borrón, Jiali Han, Julian Little, Francesco Sera, Sara Raimondi	57
8	Acral Lentiginous Melanoma of the Foot Misdiagnosed as a Traumatic Ulcer 2015 ·Journal of the American Podiatric Medical Association ·(unknown), Lauren Penn, (unknown), Russell S. Berman, Anna C. Pavlick, David Polsky	7
9	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma 2015 ·Journal of Medical Genetics ·(unknown), Matjaž Vogelsang, (unknown), (unknown), Inês Pires da Silva, (unknown), (unknown), Nathaniel H. Fleming, (unknown), Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, David Polsky, Yongzhao Shao, Iman Osman, Michelle Krogsgaard, Tomas Kirchhoff	17
10	Sensitivity of plasma BRAF^mutant and NRAS^mutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression 2015 ·Molecular Oncology ·Gregory Chang, (unknown), Yongzhao Shao, Yilong Zhang, Sarah A. Weiss, Eric M. Robinson, (unknown), Manohar R. Furtado, Dawne N. Shelton, George Karlin‐Neumann, Anna C. Pavlick, Iman Osman, David Polsky	56
11	Melanoma risk loci as determinants of melanoma recurrence and survival 2013 ·Journal of Translational Medicine ·(unknown), Shulian Shang, Christine Dominianni, (unknown), Patrick J. Scanlon, (unknown), Alexis Desrichard, Michelle Ma, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, David Polsky, Yongzhao Shao, Iman Osman, Tomas Kirchhoff	29
12	Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma 2012 ·PLoS ONE ·Molly Yancovitz, Adam J. Litterman, (unknown), Elise Ng, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, Farbod Darvishian, Paul J. Christos, Madhu Mazumdar, Iman Osman, David Polsky	212
13	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression 2011 ·Cancer Research ·Amy Rose, Laura Poliseno, Jinhua Wang, Michael Clark, Alexander Pearlman, Guimin Wang, (unknown), (unknown), Paul J. Christos, Richard L. Shapiro, Anna C. Pavlick, Farbod Darvishian, Jiří Zavadil, David Polsky, Eva Hernando, Harry Ostrer, Iman Osman	56
14	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor 2009 ·Proceedings of the National Academy of Sciences ·Miguel F. Segura, Douglas Hanniford, Sílvia Menéndez, Linsey B. Reavie, Xuanyi Zou, Silvia Álvarez-Díaz, Jan Zakrzewski, Elen Blochin, Amy Rose, Dusan Bogunovic, David Polsky, Jian‐Jun Wei, Peng Lee, Ilana Belitskaya‐Lévy, Nina Bhardwaj, Iman Osman, Eva Hernando	451
15	Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma 2009 ·Clinical Cancer Research ·(unknown), Melanie Warycha, Jan Zakrzewski, (unknown), Guimin Wang, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, Prashiela Manga, Harry Ostrer, Jülide Tok Çelebi, Hideko Kamino, Farbod Darvishian, Linda Rolnitzky, Judith D. Goldberg, Iman Osman, David Polsky	34
16	Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma 2009 ·Clinical Cancer Research ·Kathryn O’Reilly, Melanie Warycha, Michael A. Davies, Vanessa Rodrik-Outmezguine, Xi Kathy Zhou, Herman Yee, David Polsky, Anna C. Pavlick, Neal Rosen, Nina Bhardwaj, Gordon B. Mills, Iman Osman	54
17	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma 2008 ·Clinical Cancer Research ·David B. Solit, Iman Osman, David Polsky, Katherine S. Panageas, Adil Daud, James S. Goydos, Jerrold B. Teitcher, Jedd D. Wolchok, F. Joseph Germino, Susan E. Krown, Daniel G. Coit, Neal Rosen, Paul B. Chapman	146
18	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. 2007 ·PubMed Central ·Elsa F. Velázquez, Achim A. Jungbluth, Molly Yancovitz, Sacha Gnjatic, Sylvia Adams, David O’Neill, (unknown), (unknown), Paul J. Christos, Madhu Mazumdar, Anna C. Pavlick, David Polsky, Richard L. Shapiro, Russell S. Berman, (unknown), Klaus J. Busam, Iman Osman, Nina Bhardwaj	97
19	Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome 2005 ·Clinical and Experimental Dermatology ·Jülide Tok Çelebi, (unknown), Molly Wanner, David Polsky, Alfred W. Kopf	7
20	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma breakdown → 2001 ·Nature ·Marı́a S. Soengas, Paola Capodieci, David Polsky, Jaume Mora, Manel Esteller, Ximena Opitz-Araya, W. Richard McCombie, James G. Herman, William L. Gerald, Yuri Lazebnik, Carlos Cordon‐Cardo, Scott W. Lowe	769

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact